| Name | Title | Contact Details |
|---|
Lasergen is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation sequencing has led to a number of key discoveries resulting in both game-changing sequencing chemistry (Lightning Terminators™) and a more accurate sequencing platform. While focusing on the development of current cutting-edge technology, our continued drive for innovation and extensive sequencing knowledge allows us to rapidly evolve and keep pace with fast-changing advances in the sequencing industry.
Northern Surgical and Medical Supplies Ltd. is a Sudbury, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inogen`s mission to improve the quality of life of supplemental oxygen users began in 2001 when Mae, a beloved Grandmother, was prescribed oxygen therapy. Learn more about Mae`s Story here: http://www.inogen.com/about-inogen/meet-mae/. Inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. We estimate that more than 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy. Our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. We believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. With each step we take to improve our products and service, our customers take another step toward more freedom.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.
IRIS International, Inc. develops, manufactures and markets in vitro diagnostic (IVD) products, including IVD imaging systems based on neural network-based automated particle recognition (APR) software to enable high-speed digital processing to classify